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Summary 
The 52-kD  SS-A/Ro protein is one of the antigenic targets strongly associated with the au- 
toimmune response in mothers whose children have manifestations of neonatal lupus. In addi- 
tion to the cDNA clone we previously reported for the full-length 52-kD SS-A/Ro protein, 
an interesting MOLT-4 cDNA clone,  p52-2,  was found to have an internal deletion of 231 
nucleotides including the domain encoding the leucine zipper motif. To further investigate the 
nature of this deletion, genomic DNA clones were isolated from a XFIXII library. The com- 
plete gene for the full-length 52-kD protein (cx form, 52~x) spans 10 kb of DNA and is com- 
posed of seven exons. Exon 1 contains only the 5' untranslated sequence, while the translation 
initiation codon is located 3 kb downstream in exon 2, which also encodes the three zinc fin- 
ger motifs. Exon 4 encodes amino acids 168-245,  including the coiled coil/leucine zipper do- 
main. Exon 7 is the longest and encodes the rfp-like domain and the 3' untranslated region. 
The  cDNA  p52-2  can  now be  accounted  for as  a  product  of alternative  messenger RNA 
(mRNA) derived from the splicing of exon 3 to exon 5,  skipping exon 4, which results in a 
smaller protein  (5213) with  a  predicted  molecular weight  of 45,000.  An  initial  approach to 
identifying this alternatively spliced form in the human heart used a ribonuclease protection as- 
say. Using an RNA probe corresponding to bases 674-964 of the full-length cDNA, two pro- 
tected mRNA fragments were identified,  a 290-bp fragment corresponding to  expression of 
52e~ and a smaller fragment of 144 bp, the predicted size  of 5213. Using reverse transcription 
followed by polymerase chain reaction,  cDNAs  from a  16-wk fetal heart,  24-wk heart,  and 
adult heart were amplified with primers flanking exon 4. Two polymerase chain reaction prod- 
ucts were observed in each tissue,  one  1.0 kb likely representing 520~ and a second 0.78  kb, 
consistent  with  5213. The  0.78-kb  fragment identified  in  the  16-wk  heart  was  cloned,  and 
DNA sequencing confirmed the 5213 type. Immunoprecipitation of in vitro-translated 35S-la- 
beled 5213 form was performed to evaluate the antigenicity of this novel form of 52-kD SS-A/ 
Ro. 26 (87%) of 30 sera tested from mothers whose children were known to have neonatal lu- 
pus immunoprecipitated the 52[3 form. In summary, we herein describe an alternatively spliced 
mRNA encoding a novel 52 SS-A/Ro autoantigen expressed in a variety of tissues  including 
the fetal heart. Recognition of this 5213 isoform suggests that antigenicity of the 52-kD SS-A/ 
Ro protein can be independent of the putative leucine zipper domain. These findings may fur- 
ther elucidate the cellular function of the 52-kD SS-A/Ro antigen and its role in the develop- 
ment of an autoimmune disease and subsequent injury to fetal tissue. 
I 
n  addition to the 60-kD SS-A/Ro and 48-kD SS-B/La 
proteins,  another  major antigenic  target that  character- 
izes the autoimmune response in mothers whose  children 
have manifestations of neonatal lupus is the 52-kD SS-A/Ro 
protein  (1-4). A  molecular definition and sequence motifs 
for this nuclear autoantigen have been provided by the iso- 
lation  of cDNA  clones  encoding  the  full-length  protein, 
which  consists  of 475  amino  acids  (5,  6).  The  deduced 
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nal region is rich in cysteine/histidine motifs known as zinc 
fingers and belongs to the RING  finger protein subfamily, 
which includes the founding members rfp (7) and rpt-1  (8), 
and the  newly described breast cancer susceptibility gene, 
BRCA1  (9).  The  central  region  contains  two  putative 
coiled coils with heptad periodicity, one of which was pre- 
viously identified to be a leucine zipper. The COOH-ter- 
minal domain is similar to the corresponding domain in the 
rfp  protein.  The  human  52-kD  SS-A/Ro  gene  is located 
on chromosome 11  (10). Based on its homology with other 
closely related proteins that function in transcriptional reg- 
ulation such  as rpt-1,  it is reasonable to  speculate that the 
52-kD  protein  has  a  similar role.  However,  the  cellular 
function for the 52-kD SS-A/Ro is not presently defined. 
Alternatively spliced messenger  RNAs  (mRNA) l  have 
been described for transcription factors as well as inflamma- 
tory  mediators,  signal  transduction  components,  proteins 
involved in the immune response, growth factor receptors, 
and  other  housekeeping  proteins.  It  has  been  speculated 
that  such  mRNAs  either  suppress  the  translation  of the 
functional  counterpart  or represent intermediates that  can 
be further processed depending on the tissue (11). There is 
accumulating evidence for alternatively spliced forms of the 
nuclear autoantigens of the SS-A/Ro and SS-B/La systems. 
Most recently, Troster et al. described an alternative type of 
SS-B/La mRNA  in which an alternative exon  1 (exon 1') 
was used (12).  It was proposed that a  second promoter in 
the previously described intron 1 regulates the transcription 
of exon 1'. Moreover, albeit secondary to a different splic- 
ing event than that described for SS-B/La, two versions of 
the  60-kD  SS-A/Ro protein that diverge in their respec- 
tive COOH  termini have been reported (13,  14). 
Insights into  understanding  the  cellular function  of the 
52-kD  SS-A/Ro protein, its antigenicity, and to-date un- 
explained involvement in the development of fetal cardiac 
conduction  disturbances may be  gained as more  informa- 
tion  on  the  genomic  structure  becomes  available and po- 
tential alternatively spliced mRNAs  are identified. Specifi- 
cally, with  regard to  the  pathogenesis of congenital heart 
block (CHB), we hypothesized the existence of an isoform 
in which additional or deleted sequences promote access to 
autoantibodies  or  which  in  turn  may  function  to  down- 
regulate  or  up-regulate  expression of the  putative  52-kD 
SS-A/Ro. Alternative splicing as a  means  to  regulate on- 
off type gene  expression has been  described in several sex 
determining proteins  in  Drosophila  (15).  Accordingly, we 
herein define the genomic structure of the 52-kD SS-A/Ro 
protein and report the isolation of a novel alternative form 
in which exon 4 encoding the leucine zipper domain is de- 
leted. With respect to the potential role of this novel anti- 
IAbbreviations used in  this paper: aa, amino acid; CHB,  congenital heart 
block; LINE, long intersperse element; mRNA, messenger RNA; nt, nu- 
cleotide; RACE, rapid amplification of cDNA ends; RT, reverse tran- 
scription; SS,  Sj6gren's syndrome; UAS, undifferentiated autoimmune 
syndrome. 
gen  in  the  development  of neonatal  lupus,  attention  is 
focused on expression of this 5213 isoform in the human fe- 
tal heart and its recognition by sera from mothers of chil- 
dren with cardiac and cutaneous manifestations of neonatal 
lupus. 
Materials  and Methods 
MOLT-4  Cell eDNA Library Screening.  In our original report 
(5), after obtaining a partial cDNA for the 52-kD SS-A/Ro from 
a HepG2  cell cDNA library using a human  autoantibody, a  5' 
probe was generated and used to screen a MOLT-4 cell cDNA li- 
brary. Two specific clones, p52FL and p52-2, were selected for 
further  analysis.  The  longer  cDNA  (p52FL)  was  characterized 
completely and found to encode the full-length protein (5), while 
the shorter cDNA (p52-2) was not examined in detail. This study 
describes the complete sequence analysis of clone p52-2. All nu- 
cleotide positions refer to accession number M35041  unless oth- 
erwise stated (5). 
Genomic  DNA  Clones of 52-kD  SS-A/Ro.  The  full-length 
cDNA insert from clone p52FL (5) was labeled by the method of 
Feinberg and Vogelstein (16)  and  used for DNA hybridization 
screening of a human placental genomic DNA library cloned in 
the  RFIXII Vector  (Stratagene,  La Jolla,  CA).  Positive  clones 
were plaque purified and examined by restriction enzyme analysis 
and Southern blotting. Restriction fragments containing the re- 
gion of interest were identified and subcloned in pBluescript SK 
(Stratagene). 
Mapping of Transcriptional Start Sites.  The method of Hirzmann 
et al. (17) using 5' rapid amplification ofcDNA ends (RACE) to 
determine the 5'-cap-G structure of mRNA was used. Human 
placenta 5'  RACE-Ready cDNA was purchased from CLON- 
TECH  (Palo  Alto,  CA),  and  the  RACE  procedure  was  per- 
formed according to the manufacturer's instructions. The primer 
5'-TCAAGCGTGCTGCTGAAGCCATTGTCAAGT-3' (com- 
plementary to nucleotide 78-107) was used in the first PCR to- 
gether with the provided anchor primer. 10% of the PCR prod- 
uct from the first reaction was  used to set up the second PCR 
with a nested primer 5'-TTTAGGGGGTTTGGCTTTACAG- 
GGCAACTC-3' (complementary to nucleotide 21-50)  used to 
substitute for the first primer. The second PCR product was ana- 
lyzed by electrophoresis in a 4% agarose gel and subcloned using a 
cloning kit  (pCR-Script; Stratagene), and nucleotide sequences 
were determined from 12 subclones. 
DNA  Sequence Analysis.  Nucleotide sequences  were  deter- 
mined using the dye terminator cycle sequencing and a DNA se- 
quencer (373A;  Applied Biosystems Inc., Foster City, CA). Oli- 
gonucleotide primers were synthesized with a DNA synthesizer 
(394; Applied Biosystems Inc.). DNA sequences were determined 
in both strands and compiled using an alignment program (SeqEd; 
Applied Biosystems Inc.). 
RNA Isolation.  Human fetal tissues were obtained after elec- 
tive termination of normal pregnancy by dilatation and evacua- 
tion. This was done in accordance with the guidelines of the In- 
stitutional Review Board and after obtaining consent from the 
mothers.  RNA was extracted as described (18)  using the RNA 
isolation kit (Stratagene). Adult heart RNA was  obtained com- 
mercially (CLONTECH). 
RNase Protection Assays.  Plasmid p52PB containing the inter- 
nal  PstI-BamHl  (covering  bases  674-964)  was  constructed  to 
generate  an  autisense  RNA  probe.  The  PstI-BamHl  fragment 
was obtained by a partial Pstl and BamHl digestion of full-length 
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of pBluescript  SK vector. RNase protection assays were carried 
out using a kit from Ambion Inc. (RPA II; Austin, TX) accord- 
ing to  the  manufacturer's directions.  The  antisense  riboprobes 
were synthesized  by in vitro transcription (19) of p52PB linear- 
ized with HindlII using T7 RNA polymerase  and incorporating 
[32p]UTP. Each hybridization included 10-100 mg of total cellu- 
lar RNA and 5 ￿  107 cpm riboprobe with incubations for 18 h at 
42~  All riboprobes were present in >10-fold excess relative to 
the  cellular  52-kD  SS-A/Ro  mRNAs  in  the  hybridizations. 
RNase A was used at 250 U/ml and RNase T1 at 10,000 U/ml. 
The labeled probe hybridized to complementary mRNA in the 
sample mixture is "protected" from ribonuclease digestion,  sepa- 
rated on 15% polyacrylamide  gels, and visualized by autoradiogra- 
phy. 
In Vitro Transcription and Translation.  Since p52-2 represents a 
partial  cDNA for  52[3, an expression  vector containing a  full- 
length cDNA lacking exon 4 was constructed from p52FL fol- 
lowing the protocol described in the site-directed mutagenesis kit 
(Transformer;  CLONTECH).  The  primer  5'-AAGAGAGCA- 
GACTGGAAG[GAGGTGATAATTGTCCTG-3'  was  designed 
with the 5' half corresponding to the 3' end ofexon 3 and the 3' 
half to the 5' end ofexon 5. After initial priming with the mutant 
primer to generate deletion mutants, nonmutated plasmid was in- 
activated  by digestion with  Sill restriction enzyme, which  cut 
within exon 4 alone (see Fig. 1). After Sill digestion, the mutated 
plasmid  preparation  was  transformed  into  the  Escherichia coli 
DH5ci.  A  clone p5213 was  selected,  and DNA sequencing was 
used to confirm the complete in-frame deletion of exon 4.  For 
the synthesis of full-length 52[3, plasmid p5213 was linearized with 
HindlII and used as a substrate for in vitro transcription using T3 
RNA polymerase  and translation using a rabbit reticulocyte lysate 
(TNT Coupled Reticulocyte Lysate System; Promega, Madison, 
WI) in the presence of [3SS]methionine (Trans 3SS-label, 70% me- 
thionine and 15% cysteine, ICN Biochemicals,  Inc., Costa Mesa, 
CA) as described  (20). A second construct, which resulted in the 
deletion of the COOH-terminal 115 amino acid residues (equiv- 
alent to amino acids |aa] 360-475 of 52-kD SS-A/Ro), was ob- 
tained by digestion ofp5213 with the restriction enzyme Pstl be- 
fore in vitro transcription and translation. 
DNA Amplification  Method.  First-strand synthesis was accom- 
plished  using 1 ~g of poly(A  +) RNA containing 40 U  RNasin 
(Promega) in the 3' rapid amplification ofcDNA ends (3' RACE) 
system  (GIBCO BRL,  Gaithersburg,  MD)  as  described  by the 
supplier.  This cDNA was used for both 3'  RACE and reverse 
transcription (RT)-PCR.  PCR  was  performed  using a  cycler 
(TC9600; Perkin-Elmer, Oberlingen, Germany). The 50-~1  as- 
say in 15(  Taq buffer contained 2 U  Taq polymerase  (GIBCO 
BRL), 2.5 mM MgC12, 200 mM of each dNTP, 20 pmol of each 
primer, and 100 ng of cDNA. Amplification was started by heat- 
ing for 2 man to 94~  30 cycles followed,  each  consisting of 1 
rain at 94~  2 rain at 55~  and 1.5 min at 72~  The tempera- 
ture was then held for 10 min at 72~  and cooled down to 4~  6 
~1 of the respective  product was mixed with  1.5  ~1  of sample 
buffer (50% glycerol,  0.25% bromophenol blue in H20  ) and ap- 
plied to a 1.5-1.8% agarose gel in Tris-borate EDTA buffer for 
analysis. For determination of the molecular weights of the PCR 
products, 250 ng of 0X174 DNA HaelII digest  (GIBCO BRL) 
was  run  in parallel.  The  gels were  subsequently stained  with 
ethidium bromide, and photographs were taken (film 667;  Po- 
laroid Corp., Cambridge, MA). 
3' RACE amplifications were performed for 30 cycles using a 
primer spanning bases 423-443 (5'-TATGTGCCCAGTCTCG- 
GAAAC-3') located upstream of the sequence encoding the leu- 
cine zipper of the 52-kD SS-A/Ro. Amplification products were 
purified  (MicroSpin  S-400  HR  Columns; Pharmacia  Biotech 
Inc., Piscataway, NJ).  2 I~1 of purified product was amplified by 
an additional 30 cycles using a nested primer covering bases 609- 
628  (5'-AATCTAGGATTCACGCAGAG-3').  Both amplifica- 
tions were done in combination  with the Universal Amplification 
Primer of the 3' RACE kit. 
RT-PCR was performed using the same reaction conditions 
with  the  sense  primer spanning bases 423-443  as  used  in  3' 
RACE, and an antisense primer covering bases 1377-1396 (5'- 
GGCACATTCAGAGAAGGAGT-3').  After the first 30 cycles, 
the  amplification products  were  run  on  a  1.5% Tris-acetate 
EDTA gel. The lower 0.78-kb band was purified and used as a 
template in a second round of amplification with the same prim- 
ers. Selected  amplification products were  cloned using the  TA 
cloning kit (Invitrogen, San Diego, CA) as described by the man- 
ufacturer,  and DNA sequencing was used to confirm their iden- 
tity. 
Patient Sera.  Sera from 32 women whose children had neo- 
natal lupus (30 CHB, 2 cutaneous manifestations)  were tested in 
immunoprecipitation of the in vitro-translated radiolabeled  52[3 
form and the COOH-terminal truncated fragment (two mothers 
were only tested with the deletion mutant and one mother was 
only tested with the 52[3 form). Of these women, 8 had Sjrgren's 
syndrome (SS), 12 had SLE, 4 had an undifferentiated autoim- 
mune syndrome (UAS),  and 9  were  completely asyrnptomatic. 
All sera were previously demonstrated to have antibodies to the 
52-kD SS-A/Ro (defined by ELISA or SDS-immunoblot). 
Patients classified as SLE met the criteria of the American Col- 
lege of Rheumatology (formerly, the American Rheumatism As- 
sociation)  (21). Six  of the  patients  considered to  have  SS  had 
symptomatic dry eyes and/or dry mouth, plus ophthalmological 
confirmation of keratoconjunctivitis sicca (22) and/or a positive 
salivary gland biopsy according to the recommendations of T. E. 
Daniels (23). One mother whose  child had neonatal lupus was 
categorized as having SS but had dry eyes and mouth without ob- 
jective criteria,  and one mother, also best categorized  as SS, bad 
only parotid swelling as an adult, which required treatment with 
glucocorticoids.  The sera from patients with SS and SLE were se- 
lected because  they  contained anti-52-kD SS-A/Ro  reactivity 
and were from mothers whose children had neonatal lupus and 
thus do not represent a random sample of patients  with SS and 
SLE. Patients were considered to have UAS if they had symptoms 
but did not meet criteria for the diagnosis ofSLE, SS, or rheuma- 
toid arthritis. 
Of the 32 neonatal lupus sera tested, 26 (81%) had been previ- 
ously evaluated in an analysis of antigenic regions  of the 52-kD 
SS-A/Ro (20). 14 tested  were previously known to react  with 
Staphylococcus aureus V8 protease digestion fragments of the 52-k.D 
SS-A/Ro, aal-291, aa1-151, and aal-78 (type II reactivity).  11 
sera tested  were previously known to react  only with fragment 
aal-291 and did not immunoprecipitate the more NH2-terminal 
fragments  aa1-151  or aal-78 (type I reactivity).  One serum fur- 
ther evaluated in this study was marginally positive for anti-52-kD 
SS-A/Ro antibodies by ELISA but did not immunoprecipitate 
the radiolabeled  protein. Six of the maternal sera had not been 
previously tested by immunoprecipitation  or reported. 
Immunoprecipitation.  Immunoprecipitation  of  the  in  vitro 
translation products was performed as described (20). Briefly, 1 Ixl 
of  patient's  serum  was  mixed  with  50  Ixl  50%  protein  A 
Sepharose,  100  ILl 10-mg/ml BSA,  200  ~1 reaction buffer (150 
mM NaC1, 4 mM EDTA, 50 mM Tris-HC1, pH 7.4, 0.5% NP- 
985  Chan et al. 40, 0.5% sodium deoxycholate,  and 0.1% SDS), and 1 I*l of the 
labeled in vitro 52[3 translation product. For evaluation of the de- 
letion nmtant, 10 ILl ofsera and 10 I~1 of the radiolabeled  protein 
were  used.  The reaction mixtures,  in 1.5-ml Eppendorf tubes, 
were rotated at 4~  for 1-3 h. The beads were then washed four 
times  with chilled reaction buffer,  eluted, boiled with reducing 
SDS sample buffer,  and then run on 15% high-ratio monomer: 
cross-linker acrylamide  gels overnight at 7.5  mA until the bro- 
mophenol blue dye front ran off (24). The gel was then stained 
with  Coomassie  blue dye  and destained  to  visualize  molecular 
weight  markers  and  to  ensure  uniformity of immunoglobulin 
heavy and light chains precipitated in each  reaction, dried with 
heat and vacuum, and placed with film at -70~ 
Results 
52-kD  eDNA  Variant.  During  the  screening  of  the 
MOLT-4  cell  eDNA  library  to  obtain  the  full-length 
cDNA for the 52-kD SS-A/Ro as described in our original 
report (5),  clone p52-2 with a 1.4-kb insert was found also 
to be specific in the DNA hybridization reaction with the 
52-kD cDNA probe. Initial DNA sequence determinations 
showed that the 5' end ofp52-2 started at nucleotide posi- 
tion 257 (full-length cDNA 1.9 kb; reference 5), while the 
3' end matched perfectly those of other cDNAs for 52-kD 
SS-A/Ro.  By  comparison with  the  full-length cDNA,  it 
was  apparent that  there  might be  an internal deletion of 
~243 nucleotides [nt] (1.9 kb -  1.4 kb -  257nt =  243nt) 
in the p52-2 cDNA. As the complete nucleotide sequence 
was  determined for p52-2,  a  deletion of 231nt was  con- 
firmed corresponding to  a  loss  of 77  amino acid residues 
(aa168-245)  spanning the  leucine zipper  region  (Fig.  1). 
This deletion suggested that  an alternative mR.NA might 
exist,  and  thus  we  proceeded  to  characterize  the  gene 
structure for the 52-kD protein. 
Genomic Structure of the 52-kD  SS-A/Ro.  Southern blot 
analysis of human DNAs from several sources demonstrated 
that there was probably only one gene for the 52-kD pro- 
tein (5).  Two genomic clones, G5 and G33, were obtained 
from a human placenta DNA library using DNA hybridiza- 
tion with a labeled cDNA probe. As depicted in Figs. 2 and 
3, the complete gene for the 52-kD protein spans 10 kb of 
I)NA and is composed of seven exons. The 5' untranslated 
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Figure  1.  Identification of an internal deletion in  a MOLT-4  cell 
eDNA for the 52-kD SS-A/Ro. Compared with the sequence of the full- 
length cDNA p52FL, 231 bp (equivalent  to 77 aa) were found to be ab- 
sent in p52-2. Solid boxes represent the open-reading frame, and the 
numbers are the amino acid with respect to the full-length  protein. 
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Figure 2.  Hmnan gene fbr the 52-kD SS-A/Ro protein. Two ~.FIXII 
clones, G5 and G33, initially  selected by DNA hybridization,  were found 
to be overlapping as shown schematically. The  52-kD SS-A/R.o gene 
spans 10 kb of DNA and is composed of seven exons. The translational 
initiation and stop codons are located in exon 2 and 7, respectively. The 
alternative form 52[~ is derived from splicing  of exon 3 to exon 5, skip- 
ping exon 4 containing  the coiled coil/leucine zipper domain. P,,epetitive 
sequence elements  such as LINE, Alu elements, and simple repeat of the 
T and G nucleotides  (TG repeat) are indicated  as they are often found in 
introns. 
sequence is split between exon 1 and 2, separated by a 3-kb 
intron. The translation initiation codon is located in exon 
2, which encodes the three cysteine-histidine zinc fingers. 
Exon 4  encodes aa168-245,  including the leucine zipper. 
Exons 3, 5, and 6 are short exons, while exon 7 is the long- 
est  and encodes both the  rfp-like domain and the  3'  un- 
translated region. Three types of repetitive elements were 
found within the  gene for the  52-kD  protein. Repetitive 
sequences such as the long intersperse element (LINE) and 
Alu sequences were found in introns, as indicated in Fig. 2. 
A  dinucleotide TG  repeat  was  also  detected  upstream  of 
exon 4. With the exception ofa G nucleotide equivalent to 
position 239 of the cDNA, no differences were found be- 
tween the sequence of these  exons and the  cDNA previ- 
ously identified (5). 
A partial gene structure of the 52-kD SS-A/P,o contain- 
ing the last six exons has been recently published (25). This 
study  did  not  address  the  first  36nt  (part  of exon  1)  in- 
cluded in our original cDNA (5). Although the gene struc- 
tures reported by Tsugu et al.  (25)  and herein are concor- 
dant in general, there is a major difference in the location 
of exon  1,  which is  ~3  kb  upstream  of exon 2  in clone 
G33.  To confirm that exon  1 is a functional exon and to 
determine the transcriptional start site, 5' RACE was used 
to  obtain sequences upstream of the published noncoding 
sequence  (5).  Only one single band of 118  bp  (including 
the  sequence of the  anchor primer)  was  identified in the 
second PCt< product.  12 subclones containing inserts were 
sequenced; in four clones transcription starts at nucleotide 
position  I  (Fig.  3, first  arrow);  in one  clone at  position  2 
(however, missing the 5'-cap-G), one at position 5  (second 
arrow),  and six clones at position  11  (third  arrow).  The se- 
quence  data  are  consistent with  the  agarose  gel  analysis 
above, which demonstrated a single band; thus,  transcrip- 
tion begins in a relatively restricted region. The identifica- 
tion of exon 1 as delineated herein is significant, since in a 
recent report  (25)  the  promoter region would have been 
located >3 kb downstream in intron 1.  Further analysis of 
the promoter activity for the 52-kD SS-A/R.o gene will be 
provided in a separate report. 
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3226CC~CCCCCTJ~%AC-GTCTC~T~TGTTT~CGC~C~Exon2  ~G~ASAARLTMMWEEVT~  P~C~C~G~T~TGTC~TC/~T~CCT 
3326ATCT~CTGC~CCC~G%~U,C~CTGT~TC~TGT~CAC~T~C~TG~TCTCTC~GG~TC~GT~ 
IVLDPFVEPVSIEVG~SF~QE~ISQVGKGGGSV 
3426GTCC'~GTGT~CGG~TTTCTG~TCTCC~C~TCGAF~TAGCC-AACAT~TC*A~C~A~TC~CAF~G 
~FV~RQRFLLKNLRPNRQLANMVNNLKEISQEAR 
3526~~TGTG~TC,  C.ATGC,  AC~T~C~CTGTC~TC, C~CC~T~TATGT~TCT 
s  s 
3626 CGC~CGT~T~TCCCTeTT~C~TC~ACeAC~gtgaggcctaagagacacctggtgagtgcttcgttttcagagc 
agggaatgggagaggaccacctctggattggaggggttagagaaaggaggggtttacctctct~catgt~taatgtaggaggagaattataagttaaaCc 
caacct~attccccaggcgtaggagatatgcatgagaaaatgctgcaaggattaccccaccctattacttggtttgcatgggggacgaat8agctgtctt 
3966tctctgcag~TC~T  TT~CT~GAAGAAA~GC=%~TTGCa~T~C.AAGT~TGGA~ATTGCa%ATAAA~GAC,  CAGACT 
4066 Cw&KAGgtaagaatgacatcctqaaggagatcttaggctggaaggctgggc  ......  <1000 bases> ....  ataggtaccaatacctccattcccaaag 
WK 
5144 cttgggagattttcataaaaaccacctctccctttcccttgacactaaagl~C~C~C~TCTl~TTC~C~TTTG  C~ 
KTVETQKSRIHAEF~,IQQ 
5244 A~T~CT~G~C.AC, AG~ GCAGG~G~T~TC~TCCTG~C~C~C.AAGC  G 
5344 ~CC~CA~CC~.KGG~T~TCTC~TA~C~T~C~TCAC~TC~CT~TC~Gg  t  g  a  g  a  c  a  g  g  g  a  g  g  g  g  t  t  c 
AQQ@QA  QEL@SE~,nDRRCHSSALELLQ 
54{4 ccttctacaa  .....  <1200 bases> .....  tcacatcacccacagggctgatgtctcagtggcgatccagcaatccagaacttactttctqtctcttt 
6722 tctcctcagC~%GGT~T~G~CTC~Ggtaaggaggagttttctttgttagaagaggggccagca  ........  <630 bases> .......  atag 
EVIIVLER 
7426 gagtaggaga~aggagt~t~aaa~tctctttcc~Ccag~GT~GTC~TC~CCTC~C~CT~ATATTACCT~TC~C~CT~G~TGT~ 
$ESWNLKDLDITSPELRSVC 
7526 ATGT~C~T~C~T~TG/~TGCAGgtgagg~aagtt~tagttttgcgggggataa~ggggtgcagagtagatcccagggtcaggg 
HVPGLKKMLRTCA 
7626 ag~ctggatg~aacttggaggagagatggcaggtcagagcagggggaacagagatggaggtaaggaagatggtttcttcagaggtcaggaccaaggcca 
gaactggCtgatgg~CatttC~tcaCacagggaggttcac~Cct~at~ttaC~ctggagtttaCacaaaat~cccc~accacaggcacagacttagtga 
7826 ac~ccccc~atgcaaggcctga~tgtggtcct~tctctgcagTC~T~TC~T~C~CGT~T~TACTTTC-~T~G 
VHITLDPDTANPWLILSE~R 
7926C~TC~TTC~CC/~TACCTC~TC~~T~ATCCTAT~TCCT~T~C~CT~ 
RQVRLGDTQQSIPGNEERFDSYPMVLGAQMFHS 
8026GC~TG~TA~TGT~C./~CTGC~CTC~TGTCTC~TCTGT~C~C~CTTT~TTAGTT 
GKHYWEVDVTGKEAWDLGVCRDSVRRKGHFLLS 
8126CC~TC,  C.CT~T~TTTC-~TTGTG~C~C/~TATC~CT~CCCC~CTCCCC~CTTC~T~C~T~ 
SKSGFWTIWLWNKQKYEAGTYPQTPLHLQVPPCQ 
8226~GGGA~CTGC~ACTAT~TGGCAT~TCTCCTTCTACAAEAT~TGAC~T~TCCCT~TCTAC~CTTCTCTGAATGT~CTTTA~ 
VGIFLDYEAGMVSFYNITDHGSLIYSFSECAFT 
8326C,  C,  ACCTCT~CC~C~GTCCT~TTTC.KAT~T~GG~C~CCCTCT~CCCTCTGTC~CT~TATTC,  C~T~C~TC~ 
GPLKPFFSPGFNDGGKNTAPLTLCPLNIGSQGS 
8426CTG~ATDY~  ~TC~TC,  GA~CT~TCTCCC~TTC~C~TCA~C~CCCT~CTCTT~CCC~TC~TCTGAAC~CC 
8526 T~TCTCTC~TCCGGATCCC~C.AGCTTTAGC~TCAC~TC~TTCCT~CCC/~T~TGT~CCTC 
8626 C.AGTG~_C~CTCC~ATATT~CCAAACT  ~TC  TT~TCA~C~TG~TCT~C~CTTTATC-C~C~GTTTTTTT~T~CC~  T 
8726 C~TCT~AD~C,  ATG~GTC~TG~TC  8756 
Figure 3.  Complete genomic sequence for 
the 52-kD SS-A/Ro protein. Only the rele- 
vant sequences are shown, but the complete 
sequence of 13,270nt including >4-kb up- 
stream sequences derived from clone G33 has 
been  submitted  to  GenBank/EMBL  under 
accession  number  U01882. Upstream  se- 
quence, exons, and introns are indicated by 
upper case, bold-type upper case, and lower 
case nucleotide sequences, respectively. The 
region for transcriptional initiation is under- 
lined, and the three arrows indicate the start 
sites most frequently detected in  5'  RACE 
mapping. Translational start and stop codons 
are indicated by rectangles. Cysteine and his- 
tidine residues that are the backbone of the 
putative zinc fingers are indicated by inverted 
triangles. The key residues of the heptad re- 
peats within  the  two  predicted coiled coils 
(aa128-163  and  aa183-232,  underlined) are 
indicated by circles; circles with  thick lines 
are heptad repeat positions 1 or 7. 
The originally identified cDNA clone p52-2 can now be 
accounted for as a product ofmRNA  derived from splicing 
of exon 3  to exon  5,  skipping exon  4  as shown  in Fig. 2. 
The  complete sequence  corresponding to  the  52-kD  SS- 
A/Ro  gene is  13,270nt,  as shown  in  Fig. 3,  and has been 
submitted  to  GenBank/EMBL  under  accession  number 
U01882.  The newly described 52[3 form has total of 398 aa 
residues and a predicted molecular weight of 45,000. 
Fig.  4  A  is  a  summary  comparing the  splicing sites to 
known  consensus sequences  (26). The 3' splice site for in- 
tron 3 has four nucleotides that differ from the known con- 
sensus  sequence  for  3'  splice  sites.  The  consequence  of 
these  deviations might  be  an  inefficient splicing reaction, 
thereby  skipping  this  3'  splice  site  and  using  the  next 
downstream 3' splice site, with the resultant product being 
the 52[3  form that lacks exon 4.  Fig. 4  B  shows the differ- 
ence between 52<x and 52[3  analyzed by a UNIX  program 
known  as  COILS  based on  methods  described for  deter- 
mining  coiled  coil  regions  (27).  The  program  predicted 
that  there  are  in  fact  two  coiled coils for  520L, shown  as 
peaks  in  Fig.  4  B.  In  the  alternative  52[3  form,  the  first 
coiled coil is intact, whereas the second coiled coil, which 
includes the leucine zipper motif,  is deleted.  It is of note 
that the coiled coils predicted by the COILS program can 
be located in the aa sequence as heptad repeats (see Fig. 3). 
Tissue Expression of the  5213 Form.  Ribonuclease  pro- 
tection was the initial approach taken to identify the alter- 
natively  spliced form  of the  52-kD  SS-A/Ro  protein  in 
various human  tissues. As seen in Fig. 5,  the RNA  probe 
generated from p52PB  (covering 674-964)  (A) hybridized 
to  two protected fragments in a  24-wk fetal heart,  one  of 
290nt corresponding to expression of the 52~x form, and a 
smaller mRNA  fragment  of 144nt  that  likely represented 
expression of the 52[3  form (B). The intensity of the alter- 
natively spliced form increased in parallel with the quantity 
of RNA  in  the hybridization reaction.  The  expression of 
52[3 was clearly observed with 80  ~g of RNA  (B, lane 4). 
There  were  no  detectable bands  when  the  RNA  probes 
were hybridized to yeast RNA  (data not shown). The two 
fragments were also detected in 17-, 19-, and 22-week fetal 
hearts,  fetal  liver  and  lung,  and  adult  heart  (data  not 
shown). 
RT-PCR  was  used  to  identify  the  mRNA  for  52[3. 
First-strand synthesis  was  performed  using  mRNA  from 
two  14-wk  fetal hearts,  three  16-wk  fetal hearts,  one  24- 
wk  fetal heart,  and  adult heart.  The  resulting cDNA  was 
amplified with  a  sense  primer  spanning bases 423-443  in 
the  full-length  52-kD  SS-A/Ro  (upstream  of region  en- 
coded by exon  4)  and  an antisense primer spanning bases 
1377-1396.  Two products were amplified in all tissues, one 
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Size  5'Splice 
Exon  (bp)  donor  Intron 
I  52  GTAAAG  gtgagt  1 
2  457  TACCAG  g~gagg  2 
3  96  TGGAAG  g~aaga  3 
4  231  CTG~  gtgaga  4 
5  23  GGAAAG  gtaagg  5 
6  i01  GTC~  gtgagg  6 
7  946 
Donor:  AAG geaagt 
C  g 
Size 
(bp}  3'Splice  acceptor 
3173  cttacacagactttctcataetctct~ttccctttcttcttctctcccag  CCAAAC 
252  ccceattacttggettgca~gggggacgaateagctgtctttctctgcag  GAEAA~ 
i123  cttgggagattttcataaaaaccacctctccc~ttcccttgaclctaaagAAAAF.A 
1306  agtggcg~tccagcaatccagaacttactttctgtctctettctcctcag  GAGGTG 
710  gqtttggga[aggagtaggagacaggagtctcaaactctcettcccccag  GAGTGA 
303  cttagtgaactccccccatgcaaggcctgactgtggtcctcectctgcag  TCCACA 
Acceptor:  cccccccccncag 
ttttttttt 
.......  ,  ,_ _~*  .......... 
~  01  i  i  ,  J  i  ,  i  ,  ,  ' 
~{  i  l  i  i  F  i  , 
RIs~due  Poslk~ 
Figure 4.  52[5 generated from alter- 
native splicing. (A) Summary ofexons, 
introns, and splicing sites  for the 52-kD 
SS-A/Ro gene. With the exception of 
four  nucleotides (bold type) at  the  3' 
splice ofintron 3, sequenceg for 5' and 
3' splice sites are in strong agreement 
with  known  consensus sequences. (B) 
Prediction of coiled coils in 52-kD SS- 
A/Ro. The second coi[ed coil corre- 
sponding to exon 4 alone is absent in 
5213. 
a transcript of 1.0 kb, corresponding to the full-length 52e~ 
form,  and  a  second  of 0.78  kb,  the  expected  size  for  the 
5213 form (Fig. 6, lanes  I-3).  Interestingly, the larger band 
was the predominant 52Ro  isoform identified in the adult 
heart and 24-wk heart, while the two forms were of equal 
intensity in two of three 16-wk hearts. Increased expression 
of the 52[3  relative to 52a  mRNA  was observed in one of 
the  two  14-wk hearts.  The  0.78-kb  fragment identified in 
one of the  16-wk hearts was gel purified and was used as a 
template for a second amplification with the same primers. 
This amplified product was cloned, and DNA  sequencing 
unambiguously confirmed the identity of the 5213 form as 
outlined in the genomic sequence shown in Fig. 3. 
3' End of the  52-kD  SS-A/Ro  mRNA.  Since  the  full- 
length 52-kD SS-A/Ro protein is highly homologous to a 
cellular homologue of a human  transforming protein, a fu- 
sion  of the  NH2-terminal  zinc  finger  domain  of rfp  and 
COOH-terminal  domain  deriving from  a  tyrosine kinase 
(28), we sought to determine whether the sequence of the 
52e  form  in  the  fetal  heart  diverged  from  the  sequence 
published for other tissues. Our strategy was to clone flank- 
ing 3'  regions that might be derived from such  a  putative 
gene fusion using 3'  RACE  and RNA  from a  16-wk fetal 
heart,  mRNA  was  reverse  transcribed  using  a  "hybrid" 
primer consisting of oligo (dT) residues linked to a  unique 
17-base  oligonucleotide ("adapter")  primer.  Amplification 
of the resulting cDNA for the first 30 cycles used the Uni- 
versal Amplification Primer, which binds to each cDNA at 
its 3'  end,  and a  gene-specific primer  (sense primer span- 
ning bases 423-443 in the 52<x form), which would amplify 
a  fragment inclusive of exon 4.  The  1.5-kb  PCR  product 
was then purified and used in a second amplification with a 
nested primer spanning bases 609-628.  The resulting PCR 
product of 1.3 kb, the predicted size of the 52a form, was 
sequenced.  The  data demonstrated  that  the  52-kD  SS-A/ 
Ro protein expressed in the  16-wk heart is identical in se- 
quence  to  that  obtained  from  a  cDNA  library of HepG2 
(hepatocellular carcinoma)  and MOLT  4  (T  cell lympho- 
blastoma) (5). 
The 52t9 Form is Antigenic.  The plasmid p5213  contain- 
ing the  cDNA for  the  52[3  form was used to  evaluate  the 
efficiency of protein translation in a rabbit reticulocyte sys- 
tem.  The  antigenicity  of this  alternatively spliced  52-kD 
SS-A/Ro was examined by immunoprecipitation of the in 
vitro-translated 3sS-labeled protein. As shown in the repre- 
sentative autoradiograph in  Fig. 7  A, sera previously dem- 
Figure  5.  RNase protection of 52-kD SS- 
A/Ro  RNA.  (A)  Schematic diagram  of 
RNA probe and predicted fragments corre- 
sponding to the 52(x and 13 forms. (B) RNase 
protection  of 10--80 lag RNA  (lanes 1-4) 
from a 24-wk fetal heart probed with RNA 
spanning bases 674-964.  In addition to the 
predominant  protected  fragment of  290nt 
corresponding  to  52a  detected  m  all  four 
lanes, a 144nt fragment is seen in lanes 3 and 
4.  All RNA  hybridizations were  incubated 
with 50 U RNase A and 2,000 U RNase T}. 
988  Expression of52-kD SS-A/Ro 13 Form in Human Fetal Heart Figure  6.  RT-PCR  analysis of 52-kD  SS-A/Ro mRNA.  Using the 
sense  primer spanning bases 423-443  and an antisense  primer covering 
bases 1377-1936 of the known sequence for 52-kD SS-A/Ro, two frag- 
ments corresponding to the 52ci and 52~3 were amplified from cDNA of a 
16-wk fetal heart, 24-wk fetal heart, and adult heart. The 0.78-kb frag- 
ment in the 16-wk fetal heart was subcloned, and nucleotide sequencing 
confirmed that it represented 52~ type mRNA. 
Table  1.  Immunoprecipitation of the sSS-radiolabeled 52j8 
Form and COOH-terminal Truncated Fragment 
Disease  52[3  (aal-398)  52[3  (aal-283) 
ss  (n  =  8) 
Type I  1 (1)  0  (1) 
Type II  3  (3)  4  (4) 
Not tested  2  (2)  2  (2) 
No IV  0  (1)  0  (1) 
SLE (n =  11) 
Type I  6  (6)  2  (6) 
Type II  2  (3)  3  (4) 
Not tested  0  (1)  0  (1) 
UAS (n =  4) 
Type I  0  (0)  0  (0) 
Type II  3  (3)  2  (3) 
Not tested  1 (1)  0  (0) 
Asymptomatic (n =  9) 
Type I  4  (4)  0  (4) 
Type II  3  (3)  3  (3) 
Not tested  1 (2)  0  (2) 
Totals  26 (30)  =  87%  16 (31)  =  52% 
All sera tested were from mothers whose children had manifestations of 
neonatal lupus.  Type I sera  (n --  11) recognized the central region of 
the 52-kD SS-A/Ro protein including the region encoded by exon 4. 
Type II sera (n =  14) recognized the central region as well as the NH2- 
terminal region aal-78  as  discussed  in Materials and Methods and in 
reference 20. Six sera not previously tested in immunoprecipitation but 
which recognized recombinant 52-kD SS-A/Ro by ELISA or immu- 
noblot of MOLT-4  are designated "not tested." Serum from one pa- 
tient with SS was weakly positive with the recombinant 52-kD SS-A by 
ELISA but was unreactive by immunoprecipitation, here noted as "no 
IP." Two sera (one SS, one SLE) were only tested with the COOH de- 
letion fragment. One sera  (UAS) was  only tested with the 52 [~ form. 
Numbers represent those positive of the total number tested. 
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Figure  7.  Representative  immunoprecipitations  of  3SS-radiolabeled 
52[5 SS-A/Ro and COOH-terminal truncated fragment by varied sera. 
(A) Immunoprecipitations with either the 52[3 form (lanes  1-10) or the 
truncated fragment (lanes 12-20) were performed as described  in Materi- 
als and Methods. The sera used in lanes  1-10 are identical to those used in 
lanes  11-20,  respectively.  The  clinical  assignment is given above each 
lane:  SS, ASYM (asymptomatic),  or SLE. Control, two different  sera se- 
lected from six healthy donors tested.  The manifestations  of the mother's 
affected child,  CHB or skin, are noted. (/), Type I reactivity;  (10, type II 
reactivity;  nt,  not tested previously by irnmunoprecipitation. (B) Sche- 
matic  representation of the  52c~, 5213, and  52[~ deletion mutant.  The 
sticky end, present in both the 52~x and [3 forms, was previously  defined as 
aa439-475 in 52o~ (20). The 52[5 mutant, in which the COOH terminus 
(aa360-475 of 52a) is deleted by digestion of p5213 with the restriction 
enzyme PstI,  does  not contain the sticky  end.  As previously reported, 
type 1 anti-52 responses are characterized by recognition of the central re- 
gion of 52cx. Type lI anti-52 responses are characterized by recognition of 
the central region of the 52a form as well as the NH2-terminal region 
(20). 
onstrated to recognize the 52ot form by ELISA and/or  im- 
munoprecipitation  also recognized the 52[3 form.  26  (87%) 
of 30 sera tested from mothers whose children were known 
to  have neonatal lupus immunoprecipitated  the  5213  form. 
This result was  unexpected.  11  of the  26  immunoprecipi- 
tating sera were previously shown  to be reactive with aal- 
291  and not  aal-78  or  1-151,  implying that in  these  sera 
the  epitope  recognized  was  within  a  region  on  the  520L 
form encoded by exon 4  and absent in the 52[3 form (Fig. 7 
A, lanes  6-9,  type I  reactivity). 
As had been observed with immunoprecipitations of 52ci 
(20,  29), minor background reactivity was noted with con- 
trol sera  (Fig.  7  A,  lanes  1 and  5)  that increased  in parallel 
with  the  quantity  of  sera  used.  Our  earlier  experiments denmnstrated  that  a  "sticky"  region  of  the  52ot form 
mapped  to  aa439-475  (20).  Therefore,  sera  from the  af- 
fected mothers were also tested for reactivity with a PstI re- 
striction digest of the 52[3 form in which the COOH-ter- 
minal 115aa were deleted (Fig.  7 B). As expected, sera that 
had previously been shown to react with both the  central 
region of the 52c~ form as well as the NH  2 terminus immu- 
noprecipitated this PstI digest (Fig.  7 A, lanes 12-I4).  Spe- 
cifically, 12 (86%) of the 14 type II responders immunopre- 
cipitated  the  52[3 deletion  fragment  (the  two  unreactive 
sera were the weakest type II responders previously identi- 
fied).  In contrast,  of 11  antisera  that  were  reactive solely 
with  the  central region,  only 2  (18%)  were  reactive with 
the deletion fragment, and both were substantially weaker 
than the reactivity observed with the type II sera.  A sum- 
mary of the reactivity segregated by disease  and previously 
defined epitope specificity is provided in Table  1.  Immu- 
noreactivity with the 52[3 form suggests that antigenicity of 
the 52-kD SS-A/Ro protein is not dependent on the puta- 
tive leucine zipper domain. 
Discussion 
The 52-kD SS-A/Ro protein is expressed in a variety of 
human cells and tissues  and, because of its sequence motifs, 
is likely to have an important function in transcriptional ac- 
tivity. An antibody response to the 52-kD SS-A/Ro protein 
has been nearly universally demonstrated either by immu- 
noprecipitation, ELISA, or immunoblot in mothers whose 
children have manifestations of neonatal lupus (1-4). Isola- 
tion of a cDNA clone encoding the 52-kD SS-A/Ro pro- 
tein  was  accomplished  using  the  sera  from  one  of these 
mothers. The molecular characterization of the 52-kD SS- 
A/Ro  protein  is now  extended by further analysis  of the 
complete genomic structure and the description of an alter- 
native transcript. 
In addition to the cDNA clones originally reported (5), 
an  interesting  MOLT-4  cDNA  clone  52-2  was  found  to 
have  an  internal  deletion  of 231nt  including  the  domain 
encoding  the  leucine  zipper motif.  The  calculated masses 
for the full-length 52-kD SS-A/Ro  (5200  and the alterna- 
tive form (52[3) are 54,000 and 45,000, respectively. To in- 
vestigate the nature of the deletion found in clone 52-2,  a 
full-length  human  52-kD  SS-A/Ro  cDNA  was  used  to 
isolate clones from a kFIXII genomic library. The 52-kD 
SS-A/Ro gene is comprised of seven exons and covers 10 
kb of DNA. The alternative form of the 52-kD mRNA re- 
sults  from splicing of exon 3  to  exon 5,  skipping exon 4. 
DNA  sequencing  unambiguously  demonstrates  mRNA 
expression of the 52[3 form in the human fetal heart. Data 
obtained  with  RNase  protection  assay  and  PCR  suggest 
that this fore1 is present in other tissues,  including the adult 
heart. 
The identification of an alternatively spliced form of the 
52-kD SS-A/Ro that lacks a potentially functional domain 
common to  DNA binding  proteins,  nuclear  transforming 
proteins, and transcriptional regulatory proteins is of poten- 
tial  biologic  interest.  The  internal  deletion  of aa168-245, 
which includes the leucine zipper, may affect protein-pro- 
tein  interaction  and  subsequent  DNA binding,  molecular 
functions ascribed to proteins with this putative motif (30). 
Since the 52[3 form includes the NH2-terminal zinc finger 
domains,  it would be expected to retain  the same DNA/ 
RNA-binding function as that predicted for the 52r  form. 
Accordingly, the 52[3 form could function as a competitive 
inhibitor of the 52-kD SS-A/Ro protein, since both would 
compete for the same putative DNA/RNA-binding site. 
Although there is no direct evidence that the newly de- 
scribed 52[3 form is important in the pathogenesis of neo- 
natal lupus, several requisite conditions for its potential in- 
volvement  have  been  met.  First,  a  5213 form  mRNA 
transcript is expressed in the fetal heart, particularly during 
the window of presumed vulnerability, 16-24 wk of gesta- 
tional age (31).  Further analysis will reveal whether there is 
overexpression of this alternative form relative to the full- 
length form in fetal versus adult heart tissue.  Second, the [3 
form is translated, at least in an in vitro system, and is anti- 
genic,  inmmnoprecipitated  by  >80%  of numerous  sera 
from mothers whose children have neonatal lupus. 
It is  of particular  interest  that  the  majority  of mothers 
whose  children  have neonatal lupus  react with  this  novel 
5213 form, since in previous studies (20) approximately half 
of these antisera were found to react only with the central 
region of the 520~ fonn, deleted in the [3 form. As demon- 
strated  with  the  full-length  52ot  form,  there  was  back- 
ground  stickiness  noted  with  noruaal  human  sera,  which 
complicates  the  interpretation  of true  reactivity  (20,  29). 
However,  reactivity with  sera  from  affected mothers  was 
clearly greater than that observed with controls. These ob- 
servations  suggest  that  exposure  of a  novel  epitope  may 
have occurred by altered folding of the protein due to dele- 
tion of the central coiled coil region. 
To completely eliminate the background stickiness pre- 
viously attributed  to  aa439-475  of the  full-length  52-kD 
SS-A/Ro  protein,  a  truncated  form of 52[3 in which  the 
terminal 115aa were deleted was used in immunoprecipita- 
tion. As expected, all but two antisera that previously dem- 
onstrated  reactivity with  the  NH2-terminal  region  of the 
full-length 52cx form immunoprecipitated this 52[3 COOH- 
terminal  deletion  mutant.  In  contrast,  only  rare  sera  that 
were  apparently  dependent  on  the  central  region  of the 
520~ form for reactivity immunoprecipitated the  52[3 mu- 
tant. These data support several conclusions. Exposure of a 
novel immunodominant epitope in  the  52[3 form may be 
dependent  on  the  COOH  terminus.  The  NH2-temfinal 
region  spanning the  zinc  finger domains constitutes  a  re- 
stricted epitope in both 52 isoforms. The 52-kD SS-A/Ro 
protein  can  certainly be recognized in  the  absence of the 
putative leucine  zipper domain  or adjacent  NH2-terminal 
amino acid residues  197-207,  a region previously reported 
to be required for recognition by antisera from 21  patients 
with SLE (32). 
At  the  present  time,  there  is  no  definitive  proof of in 
vivo  translation  of  the  5213 protein  from  this  newly 
described alternative transcript. However, the mRNA is ef- 
ficiently translated in a rabbit reticulocyte system. The eval- 
990  Expression  of 52-kD SS-A/Ro [3 Form it: Human Fetal Heart uation of protein expression on SDS-immunoblot is com- 
plicated,  since  reactivity with  the  48-kD  SS-B/La and  its 
43-kD  degradation  product might obscure  reactivity with 
the newly described 52[3 form, predicted to be 45 kD.  To 
eliminate any confusion with SS-B/La, several sera devoid 
of 48-kD SS-B/La antibodies  as measured by ELISA were 
evaluated on SDS-immunoblot.  Intriguingly, these sera did 
not recognize any bands below the 52-kD protein (data not 
shown).  This  observation  suggests  that,  unlike  the  520t 
form,  reactivity with  the  52[3  form may be dependent  on 
native  structure  as reported  for the  60-kD  SS-A/Ro pro- 
tein  (33,  34).  Nevertheless,  on immunoblot  of transfected 
Hep-2  cells  overexpressing the  52[3  form,  rabbit  anti-52- 
kD SS-A/Ro sera clearly reacted with a band at 45 kD not 
detected in untransfected cells  (data not shown).  We have 
not  attempted  labeling  of cells  with  3ss,  since  difficulty 
with this method has been noted for the 520L form as it has 
a  long half-life relative  to most of the  common autoanti- 
gens (20). 
An  additional  finding of this  study was that  the  52-kD 
SS-A/Ro (or form) expressed in the fetal heart was identical 
to that previously published in other tissues.  The entire se- 
quence for the full-length 52-kD SSA/Ro protein is highly 
homologous to the  rfp protein,  a  cellular homologue of a 
human transforming protein,  ret  (7).  The latter is a fusion 
protein comprised of the NH2-terminal zinc finger domain 
of rfp and a COOH-terminal  domain  deriving from a ty- 
rosine kinase  (28).  The protein rfp is expressed in a variety 
of tumor cells  and  embryonic tissues.  Inasmuch as  the  ret 
fusion protein  has been shown to be  a surface membrane 
protein, one plausible mechanism for the zinc finger of the 
52-kD SSA/Ro protein to be expressed on the cell surface 
might be a DNA recombination event between the 52-kD 
protein gene and a tyrosine kinase gene as it did in the case 
of the ret oncogene. Our strategy was to clone flanking 3' 
regions that might be derived from such a putative gene fu- 
sion  using  3'  RACE,  which  generates  cDNAs  by  using 
PCR  to  amplify  copies  of the  region  between  a  single 
point in the  transcript  and the  3'  end.  Accessibility of the 
putative  52o~ form in the fetal  heart to maternal  autoanti- 
bodies is as yet not explained by tissue-specific sequences. 
In  summary,  a  novel  isoform  of the  52-kD  SS-A/Ro 
protein  is  described  in  which  the  central  leucine  zipper 
motif representing one of the two coiled coils has been de- 
leted.  In vitro-translated  protein  is recognized by antisera 
that  also  recognize  the  full-length  52ot  form,  notably  the 
majority of mothers whose children have manifestations of 
neonatal  lupus.  Further  work will  be  needed  to  examine 
the  expression  of these  two forms in affected hearts when 
they are  available  to determine  the  relative  importance  of 
52e~ or 52[3 in the putative  relationship  of anti-52-kD  au- 
toantibodies to CHB. It is anticipated that the alternatively 
spliced  form will  provide  insight  into  the  function  of the 
52-kD SS-A/Ro and its  intermolecular relationship  to the 
60-kD  SS-A/Ro.  In  turn,  this  should  facilitate  a  better 
understanding  of the  immune  response  to  the  SS-A/Ro 
autoantigens  and  its  role  in  the  development  of neonatal 
lupus. 
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